The art and science of insulin-pump therapy

Insulin Therapy

Volumn , Issue , 2002, Pages 223-244

  Marcus, Alan O ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Memorial Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36549064422     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
2. Graff MR, Rubin RR, Walker EA. How diabetes specialists treat their own diabetes: findings from a study of the AADE and ADA membership. Diabetes Educ 26: 460-467, 2000.
3. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br Med J 1: 204-207, 1978.
4. Tamborlane WV, Sherwin RS, Genel M, Felig, P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 300: 573-578, 1979.
5. Haardt MJ, Berne C, Dorange C, Slama G, Selam JL. Efficacy and indications of CSII revisited: the Hotel-Dieu cohort. Diabet Med 14(5): 407-408, 1997.
6. Tsui EY, Chiasson JL, Tildesley H, Barnie A, Simkins S, Strack T, Zinman B. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin. Diabetes Care 21(1): 93-96, 1998.
7. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48: 99-105, 1999.
8. Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes. Diabetes Care 21(10): 1627-1631, 1998.
9. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack TR. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46: 440-443, 1997.
10. Gross TM, Mastrototaro J. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Therapeutics 2: (1): S19-S26, 2000.
11. Fischer U, Freyse EJ, Salzsieder E, Rebrin K. Artificial connection between glucose sensing and insulin delivery: implications of peritoneal administration. Artif Organs 16(2): 151-162, 1992.
12. Scholtz HE, et al. Diabetologia 42(suppl): A235, 1999.
13. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 24: 326-329, 1983.
14. Hirsh RF, ed. Intensive Diabetes Management. Alexandria, VA: American Diabetes Association, 1995.
15. Bode BW, et al. Diabetes 48(1), 1999.
16. Bell DS, Ovalle F. Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy. Endocrine Pract 6: 357-360, 2000.
17. Crawford LM, Sinha RN, Odell RM, Comi RJ. Efficacy of insulin pump therapy; mealtime delivery is the key factor. Endocr Pract 6: 239-243, 2000.
18. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
19. ACE Diabetes Consensus Conference on Guidelines for Glycemic Control White Paper Review Consensus Panel, 2001.
20. Bode BW, et al. Diabetes 46(suppl 1): 143, 1997.
21. Davidson PC. The Insulin Pump Therapy Book: Insights from the Experts, pp 59-71, 1995.
22. Marcus AO, Bode B, Drexler A, et al. Patient reported experience with velosulin human insulin in continuous subcutaneous insulin infusion. Clin Ther 17(2): 204-213, 1995.
23. Shipp JC. Practical problemswith insulin pumps. N Engl J Med 306: 1369-1370, 1982.
24. Sovik O, Thordarson H. Dead-in-bed syndrome in young diabetic patients. Diabetes Care 22(suppl 2): B40-42, 1999.
25. Gross TM, Mastrototaro JJ, et al. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther 2(suppl 1): S19-26, 2000.
26. Polonsky K, Bergenstal R, Pons G, Schneider M, Jaspan J, Rubenstein A. Relation of counterregulatory responses to hypoglycemia in type 1 diabetics. N Engl J Med 307(18): 1106, 1982.
27. White N, Hollander AS, Sadler M, Daniels L. Risks and benefits of continuous subcutaneous insulin infusion (CSII) in children. Diabetes 50(suppl 2): 267, 2001.
28. Ahern J, Tamborlane WV. Pumps in kids: safe and successful. Diabetes 50(suppl 2): 268, 2001.
29. Laffel L, Loughlin C, Ramchandani N, Butler D, Laffel N, Levine BS, Anderson B. Glycemic challenges of pump therapy (CSII) in youth with type 1 diabetes (T1DM). Diabetes 50(suppl 2): 269, 2001.
30. Siegel L, Schachner H, Vargas I, Goland R. Continuous subcutaneous insulin infusion therapy in young children with type 1 diabetes. Diabetes 50(suppl 2): 271, 2001.
31. Maniatis AK, Toig SR, Klingensmith GJ, Fay-Itzkowitz E, Chase HP. Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parental perspectives and predictors of metabolic control. Pediatric Diabetes 2: 51-57, 2001.
32. White NH. Endocrinol Metab Clin North Am Dec; 29(4): 657-682, 2000.
33. Conrad SC, McGrath MT, Adi S, Greenspan LC, Lee J, Rosenthal M, Gitelman SE. Transition from multiple daily injections (MDI) to continuous subcutaneous insulin infusion (CSII): characteristics of a pediatric population. Diabetes 49(suppl 1): 409, 2000.
34. Boland EA, et al. Diabetes 49(suppl 1): 397, 2000.
35. Gibson LC, et al. Diabetes 49(suppl 1): 438, 2000.
36. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 107(2): 222-226.
37. Raskin P, Bode B, Marks J, et al. Insulin Aspart (Asp) is as effective in continuous subcutaneous insulin infusion as in multiple daily injections for patients with type 2 diabetes. Diabetes 50(suppl 1): 515, 2001.
38. Santiago JV, ed. Pregnancy. In: Medical Management of Insulin Dependent Type 1 Diabetes. 2nd ed. Alexandria, VA: American Diabetes Association, pp 90-98, 1994.
39. Jovanovic L, Druzin M, Peterson CM. Effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetic women as compared with normal control subjects. Am J Med 71: 921-927, 1981.
40. Jovanovic L, Peterson CM, Saxena BB, Dawood MY, Saudek CD. Feasibility of maintaining normal glucose profiles in insulin-dependent diabetic women. Am J Med 68: 105-112, 1980.
41. Steel JM, Johnstone FD, Hume R, Mao J-H. Insulin requirements during pregnancy in women with type 1 diabetes. Obstet Gynecol 83: 253-258, 1994.
42. Kitzmiller JL. Diabetic ketoacidosis and pregnancy. In: Queenan JT, ed. Managing Ob-Gyn Emergencies. 2nd ed. Oradell, NJ: Medical Economics, pp 44-55, 1983.
43. Gold AF, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 17: 697-703, 1994.
44. Orskov L, et al. Diabetologia Jul; 34(7): 521-526.
45. Fanelli CG, Pampanelli S, Epifano L, Rambotti AM, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 37: 1265-1276, 1994.
46. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with longterm continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 19: 324-327, 1996.
47. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypopglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 22: 1779-1784, 1999.
48. Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 32: 421-426, 1989.
49. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 107: 351-356, 2001.
50. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Am J Obstet Gynecol 164: 103-111, 1991.
51. Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 23: 579-582, 2000.
52. Akhter J, Struebing P, Larsen JL, et al. Determination of insulin requirements: excessive insulin dosages common in type 1 diabetes mellitus. Endocr Pract 4: 133-136, 1998.
53. American Association of Diabetes Educators. Education for continuous subcutaneous insulin infusion pump users (AADE position statement). Diabetes Educ 23: 397-398, 1997.
54. American Diabetes Association. Continuous subcutaneous insulin infusion (position statement). Diabetes Care 23(suppl 1): S90, 2000.
55. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care 23(suppl 1): S32-S4.2, 2000.
56. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose counterregulation after strict glycemic control of insulin dependent diabetes mellitus. N Engl J Med 316: 1376-1383, 1987.
57. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. Diabetes Care 18: 517-522, 1995.
58. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 17: 734-755, 1994.
59. Gabbe SG, Holding E, Temple P, Brown ZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol 182: 1283-1291, 2000.
60. Marcus AO, Fernandez MP. Insulin pump therapy: acceptable alternative to injection therapy. Postgrad Med 99: 125-132, 142-144, 1996.
61. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J Ped Endocrinol Metab 12: 751-758, 1999.
62. Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro J. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol 277: E561-E571, 1999.
63. Rizvi AA, Petry R, Arnold MB, Chakraborty M. Beneficial effects of continuous subcutaneous insulin infusion in older patients with long-standing type 1 diabetes. Endocr Pract 7: 364-369, 2001.